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Abstract. Amyloid- (A) deposits are seen in aged individuals of many mammalian species that possess the same aminoacid
sequence as humans. This study describes A deposition in 102 clinically characterized cattle brains from animals aged 0
to 20 years. Extracellular and intracellular A deposition was detected with 4G8 antibody in the cortex, hippocampus,
and cerebellum. X-34 staining failed to stain A deposits, indicating the non -pleated nature of these deposits. Western
blot analysis and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry revealed in
Tris, Triton, and formic acid fractions the presence of different A peptides, characterized mainly by C-terminally truncated
forms. Exploration of the genetic variability of APOE,PSEN1, and PSEN2 genes involved in Alzheimer’s disease pathogenesis
revealed several previously unreported polymorphisms. This study demonstrates certain similarities between A deposition
patterns exhibited in cattle brains and those in the human brain in early stages of aging. Furthermore, the identification of the
same A peptides reported in humans, but unable to form aggregates, supports the hypothesis that cattle may be protected
against amyloid plaque formation.
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INTRODUCTION
Amyloid- (A) is a secreted peptide produced
through sequential cleavage of the amyloid- pro-
tein precursor (APP), a transmembrane protein
widely expressed in the brain. Processed through
the amyloidogenic pathway, the majority of cleaved
A peptides are 40 residues in length (A40), and
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10154 Turin, Italy. Tel.: +39 0112686280; Fax: +39 0112686322;
E-mail: cristiano.corona@izsto.it.
a minority is composed of the 42 residue variant
(A42), which is more hydrophobic and more prone
to fibril formation than A40 [1]. Although these pep-
tides (A40 and A42) have been the dominant focus
of research, N- and C-terminally truncated or modi-
fied forms of A peptides are also found in the human
brain [2] and cerebrospinal fluid [3].
Several genetic factors are known to influence A
deposition in the Alzheimer’s disease (AD) brain.
Specifically, mutations in APP, presenilin 1 [PSEN1],
and presenilin 2 [PSEN2] genes lead with certainty
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to A aggregation and early onset AD [4]. Moreover,
three polymorphisms of APOE strongly alter the like-
lihood of developing AD and represent a relevant risk
factor for late-onset AD [5].
A40 and A42 peptides are the major components
of senile plaques that form in the cortex during aging
and the neuropathological hallmark of both familiar
and sporadic AD. A deposits may also occur in other
mammalian species, including non-human primates,
domestic carnivores, and wild animals.
The bulk of the literature on A cerebral deposition
in animals describes findings in domestic carnivores
and wild omnivores, while far fewer reports about
domestic and wild large herbivores are available to
date. Several studies have been published on sheep
[6], elephant [7], horse [8], and camel [9]. Sheep
and elephant appear to be spared cerebral A depo-
sition, except for the detection of neurofibrillary
tangles in sheep, which are concentrated in certain
areas of the neocortex [6]. Methenamine-positive dif-
fuse (preamyloid) plaques sporadically found in the
brain of horses are characterized by the accumu-
lation of the N-truncated A42 isoform [8]. Senile
plaques detected by histopathological examination in
the brain of a 20-year-old camel [9] were mostly of
the diffuse type and mainly distributed throughout the
cerebral cortex but absent in the hippocampus and the
cerebellum. A detailed characterization of A depo-
sition in the central nervous system (CNS) in cattle
has never been reported before, except in one study
[10] describing A40 and A42 peptides in bovine
aqueous and vitreous humors. Since the amino acid
sequences of A-protein are identical in bovines and
humans, the detection of senile plaques in cattle might
be expected [9, 11] and A formation might result
from similar molecular mechanisms. The aims of the
present study were to characterize A deposition in
cattle brain and correlate A fragment patterns with
age, health status, and PSEN1, PSEN2, and APOE
gene profiles.
MATERIALS AND METHODS
Animals and tissue collection
Brain sections of the frontal cortex, hippocam-
pus, cerebellum, and brainstem samples obtained at
necropsy from 102 cattle of various breeds (Piedmon-
tese, Podolica, Friesian, and mixed breed), ranging in
age from 0 to 240 months, from the Italian National
Reference Center for Animal Encephalopathies
(CEA, Turin, Italy) archive, were investigated with
different methods (Supplementary Figure 1). Fifty
cattle were healthy at death and 52 had shown neu-
rological signs (gait abnormalities, weakness, and
decreased mental status) in vivo and undergone neu-
ropathological examination. Twenty-three animals in
this latter group did not display any brain abnor-
malities and 29 presented neuropathological features
attributable to different diseases: The majority were
classified as neuroinflammatory diseases and the
remaining as toxic-metabolic or other diseases (food
poisoning, nutritional deficiencies, foreign body syn-
drome, etc.). At necropsy, the brain was removed
and divided into two parts by a sagittal parame-
dian cut. The small part was frozen at –80◦C until
immune proteomic analysis, and the other was fixed
in 10% buffered formaldehyde solution for immuno-
histochemical analysis.
Single-label immunohistochemistry (IHC)
Following formaldehyde fixation, sections of the
whole brain from each animal were cut coronally,
embedded in paraffin wax, sectioned at a thickness
of 5m, and mounted on glass slides. Slides were
dewaxed and rehydrated by routine methods and then
immersed in 98% formic acid for 10 min. To enhance
A immunoreactivity, sections were washed in dis-
tilled water and then boiled in citrate buffer (pH 6.1)
for 10 min. Tissues were then incubated overnight at
4◦C with mouse monoclonal antibody 4G8 (1:500
dilution; Signet-Covance, Emeryville, CA). After
rinsing, a biotinylated secondary antibody (1:200
dilution; Vector Laboratories, Burlingame, CA) was
applied to tissue sections for 30 min at room temper-
ature (RT), followed by the avidin-biotinperoxidase
complex (Vectastain ABC kit; Vector Laboratories)
according to the manufacturer’s protocol. Immunore-
activity was visualized using 3, 3’-diaminobenzidine
(DakoCytomation, Carpinteria, CA) as a chromogen;
sections were then counterstained with Meyer’s
hematoxylin. To test the specificity of staining,
primary antibodies were omitted. Furthermore, to
simultaneously localize lipofuscin and A in the
same tissue sections from older cattle, a combined
IHC: Histochemical (IHC: HC) staining protocol
was performed, incubating sections with 1% peri-
odic acid for 10 min and Schiff’s reagent (Carlo Erba
Reagents, Cornaredo, Italy) for 15 min before 4G8
immunostaining [12]. Human AD brain tissue was
used as positive control. A deposition in the four
brain regions was graded according to the severity of
immunoreactive lesions visualized by 4G8 antibody.
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The intensity grade of deposition was scored as none
(0), slight (1), moderate (2), and marked (3).
Immunoﬂuorescence
X34 staining
Several brain areas with greater amounts of A
deposition were selected for X34 staining, a highly
fluorescent derivative of Congo red. Fixed brain tis-
sues were stained with methoxy-X34 diluted 1:250
in 40% ethanol for 10 min at RT and analyzed under
confocal laser scanning microscopy (SP8, Leica
Instruments, Heidelberg, Germany).
Amyloid-β and glia detection
Brain sections staining positive for A by IHC
were selected for immunofluorescence studies per-
formed according to the protocol described above.
Double labeling to evaluate the relationship between
astrocytes and microglia cells with A deposits
was performed. Tissue sections from frontal cor-
texes were dewaxed, rehydrated, formic-acid treated,
and boiled in citrate buffer (pH 6.1), as in the
IHC protocol described above. Primary antibodies
4G8 (1:100 dilution; Signet-Covance) and rabbit
polyclonal Iba-1(1:100 dilution; Wako Chemicals,
Richmond, VA) to visualize microglial cells or rab-
bit polyclonal glial fibrillary acidic protein (GFAP)
(1:100 dilution; DakoCytomation) to evidence astro-
cytes were applied for 1 h at RT. Tissue sections
were then incubated at RT with either Alexa fluor
555 or Alexa fluor 488 secondary antibodies (1:250
dilution; Invitrogen, Life Technologies, Carlsbad,
CA), respectively, for 15 min. Sections were exam-
ined under confocal laser scanning microscopy (SP8,
Leica Instruments). Secondary antibody specificity
was tested by applying these antisera without the pri-
mary antibodies. Glia deposits were considered to
be associated if their cell bodies or processes were
confined within the area of amyloid deposits.
Immunoblotting for Iba-1 and GFAP
Thirty cortex pools were collected from cattle
with low (n = 15) and high presence (n = 15) of A
detected by IHC. Lysis buffer 1X was added to
each sample and centrifuged at 14000 rpm at 4◦C
for 15 min. The supernatant was retained, loaded
with 2% Laemmli buffer, and boiled at 99◦C for
5 min; samples were then loaded onto polyacry-
lamide gel and separated by electrophoresis. Proteins
were transferred to PVDF membranes (GE Health-
care/Amersham Biosciences, Little Chafont, UK)
using Wet Blot at 150V for 1 h. Membranes were
blocked at RT for 1 h and incubated with primary
antibodies (Iba-1 for microglia 1:100 and GFAP for
astrocytes 1:10000, Millipore, Darmstadt, Germany).
After rinsing, membranes were incubated at RT for
30 min with secondary antibodies (diluted 1:12000).
Blots were developed using chemiluminescent sub-
strate (Invitrogen) for 5 min, and proteins were
visualized on autoradiographic films.
Biochemical compartmentalization
Strips of tissue (300 mg) were dissected from the
frozen cortex, hippocampus, cerebellum, and brain-
stem of each animal. A 4-step extraction protocol
modified from Steinerman et al. was used [13].
Tissue was mechanically homogenized in Tris extrac-
tion buffer and then sonicated. After centrifugation
(100,000 × g, 4◦C, 1 h), the supernatant was retained
as the Tris-soluble fraction. The pellet was homoge-
nized again in Triton extraction buffer, sonicated, and
centrifuged (100,000 × g, 4◦C, 1 h), and the super-
natant was retained as the Triton-soluble fraction.
The remaining pellet was homogenized in sodium
dodecyl sulfate (SDS) extraction buffer, spun, and
the supernatant was saved as the SDS-soluble frac-
tion. The remaining pellet was homogenized in 70%
formic acid (FA) to obtain the FA-extracted frac-
tion, and neutralized in 20 volumes 1M Tris. These
fractions are defined by their biochemical proper-
ties; however, they are predicted to be enriched with
proteins from distinct cellular compartments: Extra-
cellular soluble (Tris), intracellular soluble (Triton),
membrane-associated (SDS), and insoluble (FA) pro-
teins. Because each fraction may also contain proteins
from other cellular compartments and A may
spill over between compartments during the extrac-
tion procedure, these fractions do not correspond
precisely to cellular compartments.
Immunoblotting for Aβ
Forty-seven samples (30 from frontal cortex,
10 from cerebellum, and 7 from brainstem) were
obtained from 34 cattle. Sample buffer 3X was
added to Tris, Triton, and SDS brain fractions, son-
icated, and boiled for 5 min. Each sample and A
peptides 1–38, 1–40, and 1–42 were loaded onto
urea gels and separated by electrophoresis. Proteins
were transferred to polyvinylidene fluoride (PVDF)
membranes (GE Healthcare/Amersham Biosciences)
using a Trans-Blot Semi Dry for 1 h. Membranes
were boiled in a microwave for 3 min in TBS and
incubated with primary monoclonal antibody (6E10
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antibody, diluted 1:500, Covance) at 4◦C overnight.
After rinsing, membranes were incubated at RT for
30 min with AP-conjugated anti-mouse secondary
antibody (diluted 1:12000, Invitrogen). Blots were
developed using chemiluminescent substrate (Invit-
rogen) for 5 min and proteins were visualized on
autoradiographic films.
Surface-enhanced laser desorption/ionization
time-of-ﬂight (SELDI-TOF) mass spectrometry
Thirty brain samples (Tris, Triton, and formic-
acid fractions for each brain) were analysed by
SELDI-TOF-MS. Three l of the specific mono-
clonal antibodies (mAbs) (6E10 + 4G8) (Covance)
at a total mAbs concentration of 0.125 mg/ml (con-
centration of each mAb was 0.0625 mg/ml) were
incubated for 2 h at RT to allow covalent binding to
the PS20 ProteinChip Array (Bio-Rad, Hercules, CA,
USA). Unreacted sites were blocked with Tris-HCl
0.5 M, pH 8 in a humid chamber at RT for 30 min.
Each spot was washed three times with PBS con-
taining 0.5% v/v Triton X-100 and then twice with
PBS. Spots were coated with 5l of sample and
incubated in a humid chamber overnight. Each spot
was washed first three times with PBS containing
0.1% v/v Triton X-100, twice with PBS, and finally
with deionized water. Onel of -cyano-4- hydroxyl
cinnamic acid (Bio-Rad) was added to the coated
spots (Bio-Rad). Mass identification was performed
using a ProteinChip SELDI System, Enterprise Edi-
tion (Bio-Rad).
Genetic analyses
APOE
DNA was isolated using a NucleoSpin Tissue
kit (Macherey-Nagel, Du¨ren, Germany) from frozen
brain tissue of 21 cattle. A genomic region of
∼1.8 Kb, encompassing exon 2 to exon 4 of the
bovine APOE gene was PCR amplified. The selected
region included the entire APOE open reading frame
(ORF) (Fig. 1). PCR primers were designed using
the Primer3 application (http://primer3.ut.ee/); their
sequences were: APOE Bt Ex2 F (5’ CCAATCG-
CAAGCCAGAAG 3’) and APOE Bt Ex4a R (5’
GAGACTCGGGGTGGGAGTA 3’). Thermocycling
parameters were an initial denaturation step (95◦C,
10 min) followed by 40 cycles of denaturation (94◦C,
1 min), annealing (57◦C, 1 min), and extension
(72◦C, 2 min). APOE sequences were determined
by direct DNA sequencing of PCR products on
an ABI 3130 Genetic Analyser (Life Technolo-
gies) by Big Dye terminator v. 3.1 cycle-sequencing
using the amplification primer pairs and two
internal primers, APOE Bt Ex3 F (5’ GAGGAGC-
CCCTGACTACCC 3’) and APOE Bt Ex4b R (5’
ACACCCAGGTCATTCAGGAA 3’). The sequence
reactions were prepared as follows: 2l sequencing
buffer 10x, 2l of Big Dye Terminator v3.1, 3.2 pmol
of the sequencing primer (PCR primers), 50–100 ng
of template DNA in a final volume of 20l. AllAPOE
sequences were assembled using the SeqMan II pro-
gram (Lasergene package, DNASTAR Inc., Madison,
WI) to obtain a consensus sequence for each sample.
Polymorphic nucleotides were annotated and the final
consensus sequences were assembled into a single
dataset. Each variable site was numbered based on the
corresponding position in the bovine APOE sequence
(GenBank acc. no. NC 007316.5). Finally, allele fre-
quencies of detected polymorphisms were calculated.
PSEN1 and PSEN2
To amplify the entire ORF of PSEN1 and PSEN2
genes, an approach based on amplification and
sequencing of RNA transcripts was selected from 19
brain tissues for PSEN1 and from 18 brain tissues
for PSEN2. This was done to avoid having to set
up several PCR reactions to cover all coding exons
of the two genes, since PSEN1 and PSEN2 loci
comprise 11 and 10 short coding exons, respec-
tively, separated by long introns. Total RNA was
isolated using Trizol (Life Technologies) and then
DNase-treated employing Baseline-ZERO Dnase
(Epicentre, Madison, WI). One g of total RNA
was reverse transcribed using a high-capacity cDNA
Reverse Transcription kit (Life Technologies) and
cDNA was used as a template for amplification
of the entire ORFs of PSEN1 and PSEN2. PCR
primers for PSEN1 were designed using Primer3 to
amplify the complete ORF in a single reaction. Their
sequences were: PSEN1 PCR 1F (5’ GCAGC-
CTGTGAGGTCCTTAG 3’) and PSEN1 PCR 4 R
(5’ CACCGGAAAATCACCTTTGT 3’) giving
a PCR product of 1653 bp. PCR primers for
PSEN2 were designed using Primer3 to produce
two overlapping PCR amplicons covering the gene
ORF. Their sequences were: PSEN2 PCR 1F (5’
AGCAGGTGTGCTAAGGCACT 3’) coupled with
PSEN2 PCR 3 R (5’ ACAGCACAGCCACAA-
GATCA 3’), giving a PCR product of 843 bp,
and PSEN2 PCR 2F (5’ CAGGAGGCCTACCT-
CATCAT 3’) coupled with PSEN2 PCR 4 R (5’
TACCGCTTCCTACAGCTTCC 3’), giving a PCR
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product of 708 bp. Thermocycling parameters
were an initial denaturation step (95◦C, 10 min)
followed by 40 cycles of denaturation (94◦C,
1 min), annealing (56◦C, 1 min), and extension
(72◦C, 2 min). Cycles were raised to 45 for PSEN2
PCR 2F/PSEN2 PCR 4 R primer pair. Sequences
were obtained by direct DNA sequencing of the
PCR products on an ABI 3130 Genetic Analyser
(Life Technologies) by Big Dye terminator v. 3.1
cycle-sequencing using the amplification primer
pairs and the addition of two internal sequenc-
ing primers for PSEN1. Their sequences were:
PSEN1 SEQ 2F (5’ CCTCATGGCCCTGGTA
TTTA 3’) and PSEN1 SEQ 3 R (5’ CGGTC-
CATTCTGGGAGGTA 3’). The sequence reactions
were prepared as follows: 2l sequencing buffer
10x, 2l Big Dye Terminator v3.1, 3.2 pmol of
the sequencing primer, and 50–100 ng of template
DNA in a final volume of 20l. All sequences
were assembled using the SeqMan II program
(Lasergene package, DNASTAR Inc.) to obtain a
consensus sequence for each sample. Polymorphic
nucleotides were annotated, and the final consensus
sequences were assembled into a single dataset for
each PSEN gene. Each variable site was enumer-
ated based on the corresponding position in the
bovine PSEN1 and PSEN2 sequences (GenBank
acc. nos. BC151458 and NM 174440.4). Finally,
allele frequencies of detected polymorphisms were
calculated.
Statistical analysis
Several logistic regression models were set up
to assess the relationship between the animal’s
health status and the genetic, immunoproteomic, or
immunohistochemical patterns. A logistic regression
model was also used to investigate the relationship
between the proteomic pattern, genetic profile, and
animal age. Sex and breed were entered in the model
as confounding variables. The distribution of IBA and
GFAP values for different grades of A deposition
was described by boxplots. The association of IBA
and GFAP values with A deposition grading was
analysed using a Kruskal-Wallis test. Statistical data
analysis was performed using STATA 11 (StataCorp.
2009. Stata Statistical Software: Release 11. College
Station, TX, StataCorp LP).
RESULTS
Single-label immunohistochemistry
IHC analysis for A revealed 4G8-
immunoreactivity in 59 out of 102 (57%) cattle
brains. Immunopositive deposits presented two
Fig. 1. IHC and IHC: HC immunoreactive deposits in different brain areas. A) 4G8-deposits in the frontal cortex. Bar = 250m. B) 4G8-
deposits in the frontal cortex (Bar = 50m) with magnification of intraneuronal localization (100x). C) 4G8-deposits in the hippocampus.
Bar = 50m. D) 4G8-deposits in the cerebellum. Bar = 50m. E) Absence of 4G8-deposits in the brainstem. Bar = 50m. F) IHC: HC,
4G8-deposits (arrow) and lipofuscin (arrowhead) in the frontal cortex. Bar = 20m.
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different patterns classified as intracellular and
extracellular. The intracellular pattern was identified
in 2 out of 59 (3%) cattle and was characterized by
fine, randomly dispersed immunoreactive granules
around the nucleus. The extracellular pattern was
identified in 16 out of 59 (27%) cattle and was
characterized by aggregates frequently associated
with glial cells. The coexistence of intracellular
and extracellular patterns was seen in 41 out of 59
IHC-positive cases. The remaining 43 cases resulted
completely negative for A immunoreactivity
(Table 1). Immunostaining of samples from the
frontal cortex was slight to marked; intracellular A
deposition patterns were observed in the neurons
of the external pyramidal and granular layers and
extracellular patterns in the molecular layer. A
immunolabeling in the hippocampus appeared
slight to moderate, with extracellular A granules
scattered within the neurons of the dentate gyrus.
Both intracellular and extracellular patterns were
identified in the cerebellum, Purkinje cell bodies,
and the molecular layer. No A deposits were
observed in the brainstem; no A immunoreactive
plaques or congophilic angiopathy were found in any
of the tissue sections (Fig. 1A–E). Lipofuscin was
predominantly present in the cytoplasmic regions of
neurons exhibiting prominent 4G8 immunolabelling.
Lipofuscin deposits were not co-localized with A
in the neurons but were distributed in distinct cellular
compartments (Fig. 1F). The relationship between
the presence of A and animal age was investigated
using a logistic model: via IHC, both intracellular and
extracellular A deposition in cattle brain increased
with age (p < 0.000). The model also highlighted a
close relationship between the animal’s health status
and 4G8 immunoreactivity. In particular, the IHC-
positive animals had a 14-fold higher risk to develop
neurological disease (95% confidence interval [CI]
2.7 to 73.8), and A accumulation occurred earlier
(starting from 12 months) in the diseased animals as
compared with the healthy ones (120 months).
Immunoﬂuorescence
Aβ deposits and glia detection
All the examined brain sections were negative to
X34 staining, indicating the non -pleated nature of
A deposits. Double immuno-labelling with GFAP
and 4G8 of frontal cortexes showed hypertrophic
astrocytes that were occasionally observed wrapping
A deposits inside neuronal cell bodies or in the
neuropil (data not shown). Dual immunofluorescence
with Iba-1 and 4G8 confirmed microglia involvement
in the extracellular A deposition pattern. Activated
microglial cells were localized in proximity to A
deposits. Some microglia and cell processes were
distributed around the periphery of the aggregates,
revealing active phagocytic activity (Fig. 2). No A
or glia immunolabeling was observed by omitting the
primary antibodies.
Immunoblotting for Iba-1 and GFAP
To quantify the extent of glial cell expression,
western blot analysis (WB) of GFAP in the whole
cortex homogenates of cattle with low or high grade
A deposition revealed by IHC showed no differ-
ences in GFAP protein expression (Supplementary
Figure 2). WB analysis of IBA-1 in the whole cor-
tex homogenates showed a marked increase in IBA-1
protein expression in animals with high amounts of
A protein (Supplementary Figure 3). The boxplots
in Fig. 3 show the distribution of GFAP and IBA (rel-
ative) values for low and high grade A deposition,
respectively. There was no statistically significant dif-
ference in the GFAP values between the two groups
(Kruskal-Wallis, p < 0.09), whereas IBA increased
with A deposition and there was a significant dif-
ference in its concentration between the low and
high-grade groups (Kruskal-Wallis, p < 0.0001).
Biochemical characterization of Aβ deposits
Frozen brain specimens were analyzed by
immunoblot analysis. A1–38, 1–40, 1–42, and 3–42
were detected in 10 out of the 34 animals examined.
Specifically, A 1–38 was found in the cortex in 4
out of 10 positive animals, A 1–40 in the cortex of 7
out of 10 positive animals, and A 1–42 in the cortex
of 7 out of 10 positive animals. A 3–42 was found
in the cortex of only 1 out of 10 positive animals; 2
cerebella out of 8 were positive for A peptides: A
1–42 in 2 cerebella out of 2 positive cases and A
1–40 in only 1 cerebellum out of 2; no A peptides
were detected by WB analysis in the 7 brainstems. In
all cases, the signal intensity was weaker than the sig-
nal detected in human AD brain (Fig. 4). Statistical
analysis showed a correlation between WB-positive
cattle for the presence of A peptides with general
4G8 immunoreactivity, although this datum was not
statistically significant (odds ratio [OR] 4.7, 95% CI
0.7 to 29.8).
SELDI-TOF MS immunoproteomic analyses
Immunoproteomic analysis with two different anti-
bodies directed against A (6E10 and 4G8) in
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Table 1
A deposition patterns
Intracellular Total Extracellular Total Coexistence Total Negative Total
animals = 2 animals = 16 animals = 41 animals = 43
No. of animals 1 1 11 5 17 24 24 19
Age range (months) 36 60 8–120 120–199 36–120 120–199 0–120 8–112
Neurological signs no decubitus decubitus no decubitus no tremors no
paresis paresis paresis paresis
d.m.s. d.m.s. ataxia
d.m.s.
Main affected areas Frontal, parietal Hippocampus Frontal cortex Brainstem
cortexes
Intensity IHC signal Slight Slight to moderate Slight to marked None
A deposition patterns based on the localization of 4G8 immunoreactivity. (d.m.s.: Decreased mental status).
Fig. 2. Double immunofluorescence staining with IBA-1/4G8. Immunofluorescent A deposits associated with microglial inflammation: A)
Activated microglia (green, Iba1) and (B) A deposits (red, 4G8) in the frontal cortex of brain cattle. C) Merge. Bar = 13.1m.
Fig. 3. Boxplots of western blot analysis using IBA-1 and GFAP. A) IBA-1 values for low and high-grade A deposition (total n = 32).
B) GFAP values for low and high-grade A deposition (total n = 29).
30 brain samples revealed, in the three fractions
(Tris, Triton, and formic acid), the presence of
12 different A peptides (10 C-terminally trun-
cated and 2 N-terminally truncated), the smallest
being A1–18 (2166 Da) and the largest A 1–42
(4515 Da). The relative amount of C-terminally trun-
cated A peptides was highest in 1–37 (4074 Da)
and progressively decreased in 1–40 (4329 Da) and
1–42 in the Tris fractions, while in the Triton
fractions the highest amount was observed in A
1–40 > 1–37 > 1–34 (3787 Da). Finally, in the formic-
acid fractions the highest amount was observed in A
1–34 > 1–42 > 1–37 (Table 2). A 1–42 was present
in the insoluble fractions (Triton and formic acid)
and N-terminally truncated A peptide 10–40 was
present in the formic-acid treated fractions. A 1–37
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Fig. 4. Western blot analysis of A using 6E10 antibody. A peptides 1–38, 1–40, and 1–42 in Tris, Triton, and SDS fractions of cattle
cortex pools. Synthetic A peptides were used as controls.
Table 2
SELDI-TOF MS signal intensities (int.) and relative percentages (%) of A peptides in cattle
brains in Tris, Triton and formic-acid fractions
Peptide Tris int. (%) Triton int. (%) Formic Acid int. (%)
A 1–18 0 0.08 ± 0.4 (0,6) 0
A 1–28 0 1.35 ± 6.7 (10,8) 0
A 10–40 0 0 1.05 ± 1.5 (8,70)
A 1–30 0.11 ± 0.4 (1,63) 0.65 ± 1.6 (5,20) 0
A 1–33 0 0 0.57 ± 1.7 (4,7)
A 1–34 0.15 ± 2.0 (2,2) 2.26 ± 1.7 (18,1) 4.4 ± 6.2 (36,7)
A 1–36 0.53 ± 1.4 (7,8) 0 0
A 5–42 0 1.58 ± 4.2 (12,6) 1.33 ± 3.1 (11,1)
A 1–37 2.23 ± 4.6 (33,2) 3.03 ± 6.9 (24,3) 1.74 ± 4.1 (14,5)
A 1–38 0.39 ± 1.4 (5,8) 0.33 ± 1.0 (2,6) 0
A 1–40 2.09 ± 2.0 (31,1) 3.06 ± 2.2 (24,5) 0
A 1–42 1.21 ± 3.0 (18) 0.11 ± 0.5 (0,8) 2.89 ± 2.1 (24,1)
and A 1–40 were predominant in both the Tris and
Triton fractions in the young animals (<36 months),
whereas A 1–34 and 1–42 were prevalent in the
formic-acid fractions, and A 1–40 in the Triton
fractions in the aged animals (Fig. 5A, B). A pep-
tide 1–34 was expressed in all three fractions in the
healthy animals, with a relevant presence of A 1–40
(Triton) and 1–42 (Tris and formic acid) (Fig. 5C). In
the diseased cattle, there was a large variety of A
peptides, with A 1–37 and 1–34 present in all three
fractions, A 1–42 mostly in the formic-acid fraction,
A 1–40 in the Tris and Triton fractions, and A
5–42 (4050 Da) in the Triton and formic-acid frac-
tions (Fig. 5D). The SDS fraction was not analyzed
because of the analytical interference of SDS. Statis-
tical analysis showed that A 10–40 and A 1–42
correlated (albeit not statistically significant) with
extracellular IHC-positive results in the cortex (OR
2, 95% CI 0.3 to 15.4; OR 2.2, 95% CI 0.1 to 42.7,
respectively). In the frontal cortex, the presence of
A10–40 also correlated with the IHC intracellular-
positive result.
Genetic analyses
APOE
Sequence analysis of the APOE gene of 21 cattle
resulted in the identification of nine single nucleotide
polymorphisms (SNPs). Table 3 presents the poly-
morphisms, their position in the sequence, and
relative allele frequencies (numbering refers to NCBI
reference sequence acc. no. NC 007316.5 starting
from the coding sequence in exon 2). The three poly-
morphisms not reported in the NCBI Gene reference
database were one non-synonymous mutation in exon
2 (22 G/T, codon 8, Val−→Leu) and two SNPs in
intron 2 (54 G/A) and intron 3 (725 G/T). Two further
mutations located in exons 3 and 4 were synony-
mous (exon 3, 575 C/G, codon 32, Thr−→Thr and
in exon 4, 1215 T/C, codon 146, Ser−→Ser). SNPs
at positions 824 (intron 3) and 1215 (exon 4) were in
complete linkage disequilibrium. A statistically sig-
nificant association was found between the APOE
allele 725-T in intron 3 and the presence at WB of
A peptides 1–38 (p = 0.000), 1–40 (p = 0.005), and
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Fig. 5. Mean peak intensity of A peptides (A±SE) measured in Tris, Triton, and formic-acid fractions of cattle brains. A) Cattle less than
36 months old. B) Cattle more than 36 months old. C) Healthy cattle. D) Diseased cattle.
Table 3
Polymorphisms, their position in the APOE sequence, and relative
allele frequencies
Polymorphism location APOE gene Minor allele
(Ref. Seq. NC 007316.5) region frequency
22 G/T (codon 8, Val−→Leu) exon 2 0.08
54 G/A intron 2 0.06
57 C/G intron 2 0.24
75 T/C intron 2 0.26
133 C/G intron 2 0.37
575 C/G (codon 32, Thr) exon 3 0.61
725 G/T intron 3 0.09
824 A/G intron 3 0.38
T1215 T/C (codon 146, Ser) exon 4 0.38
1–42 (p = 0.016) in the cortex, whereas the absence
in the WB profile of peptides 1–38 in the cortex was
associated with allele133-G in intron 2 and 824-G in
intron 3.
PSEN1 and PSEN2
Sequence analysis of PSEN1 of 19 cattle revealed
conservation of this gene since no SNPs were
detected in the ORF. Having sequenced RNA
transcripts, we were able to detect two differ-
ent length variants differing by 12 nucleotides
and corresponding to computationally predicted
bovine PSEN1 transcript variants (GenBank acc. nos.
XM 005211931-XM 005211937). This difference in
length between transcripts relies on a polymorphism
located in the coding DNA sequence (CDS) of the
Table 4
Polymorphisms, their position in the PSEN1 and PSEN2
sequences, and allele frequencies
Polymorphism location
PSEN1 (Ref.Seq. BC151458) Minor allele frequency
290 302ins GTACGTAGCCAG 0.40
(codon 25, ValArgSerGln insertion)
PSEN2 (Ref.Seq. NM 174440.4) Minor allele frequency
85 C/T (codon 29, Arg−→Cys) 0.03
198 C/T 0.08
264 T/C 0.03
849 G/A 0.36
973 975delAGA (codon 325, Glu deletion) 0.36
gene (290indelGTACGTAGCCAG; numbering rela-
tive to NCBI reference sequence acc. no. BC151458),
resulting in the insertion/deletion of a tetrapeptide
(ValArgSerGln) after codon 25 of the PSEN1 pro-
tein (Table 4). Sequence analysis of PSEN2 of 18
cattle identified five mutations in the ORF: Four
SNPs and one indel polymorphism. Table 4 presents
the polymorphisms, their position in the reference
sequence, and allele frequencies (GenBank acc. nos.
NM 174440.4; numbering relative to the ORF). The
two not reported in the NCBI Gene reference database
were one non-synonymous mutation at position 85
(Arg−→Cys) and one indel polymorphism deter-
mining the deletion of an AGA triplet at position
973–975. This deletion causes the loss of one glu-
tamic acid (Glu) residue in the resulting PSEN2
protein and was detected at 36% allele frequency. The
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indel was in complete linkage disequilibrium with the
synonymous polymorphism at position 849 (G/A).
Statistical analysis highlighted a significant associa-
tion between allele 290 302ins GTACGTAGCCAG
of PSEN1 and the absence of peptide 1–33 (p = 0.02)
in the formic-acid fraction of the cortex. Full analy-
sis of the A peptides in the three fractions showed a
correlation between the presence of A peptide 1–40
(OR 6.2, 95% CI 0.12 to 311.7) in the cortex and
the presence of 290 302insGTACGTAGCCAG, but
the difference was not statistically significant. Allele
973 975delAGA of PSEN2 was associated with the
absence of A peptide 1–34 (p = 0.02) in the formic-
acid fraction of the cortex. This allele also showed a
correlation with a positive result for the presence of
intracellular A deposition in IHC (OR 3.8, 95% CI
0.4 to 39.9), but the difference was not statistically
significant.
DISCUSSION
Aging entails morphological, neurochemical, and
functional modifications of the brain caused by detri-
mental factors such as oxidative stress and altered
cell metabolism; however, the molecular mechanisms
underlying aging remain elusive. To date, animal
models, including rodents, dogs, and non-human pri-
mates, provide only partial clues to the progressive
accumulation of toxic proteins during aging.
Here we demonstrated an age-related progression
of A deposition in cattle brain as occurs in humans.
Granular aggregates of A peptides, without the pres-
ence of plaques, were observed in the cattle brains.
Although a similar A deposition pattern has been
described in aged domestic cats, cheetahs, and leop-
ards, the presence of an alternative N-terminal epitope
of A peptides is thought to be responsible for their
low propensity to aggregate in these felines. An alter-
native explanation for this phenomenon can be given
for cattle, where N-terminal modification has not
been reported and where the A sequence is sim-
ilar to that in humans who naturally develop A
plaques during aging. The deposits observed in the
cattle brains were constituted by A protein that was
not organized in fibrils and that lacked -sheet sec-
ondary protein structure. It is conceivable, therefore,
that amyloid deposits are intermediate cleavage prod-
ucts of APP detectable in the earlier stages of A
deposition. Similar deposits are frequently detectable
in some forms of human dementias [14] and in non-
demented elderly [15].
A deposition seen in both the intracellular and
extracellular patterns increased with advancing age.
Similar results are described in healthy humans,
where postmortem studies have shown that A accu-
mulation appears in the first year of life, increases
in childhood, and remains high throughout adult-
hood, indicating that A immunoreactive material in
the cell body reflects normal neuronal metabolism
and is not a neuronal pathology [16, 17]. This
age-dependent A deposition is similar in other
animal species such as dogs, cats, and monkeys
[18–21]. In the cattle, A deposition seemed to start
with an extracellular pattern and then evolve toward
coexisting patterns of intracellular and extracellu-
lar deposits prevalently seen in the older animals.
According to LaFerla, previously secreted A in
the form of an extracellular pool may be taken up
by cells and internalized through receptors or trans-
porters into intracellular compartments over time
[1].
Although 52 out of 102 cattle displayed signs of
neurological disease, a complete evaluation of cog-
nitive status was not possible. This is a limitation
of our retrospective study. Of note is that cognitive
decline, as described in other animal species [22],
has not been reported in cattle. Since these animals
demonstrated gait abnormalities, brainstem or spinal
cord seem to be more involved than hippocampal
or frontal cortex, the two areas implicated in cog-
nitive impairment. Moreover, we observed a strong
relation between health status and A deposition:
IHC-positive animals had a 14-fold higher risk to
develop neurological pathology probably due to the
impairement of the phagocytic abilities of microglial
cells [23]. Furthermore, the fact that diseased cattle
have an increased risk to accumulate A in the brain
provides evidence that the presence of neuropatho-
logical disease induces early accumulation of A.
It is conceivable, therefore, that an underlying neu-
ropathological process may speed up cerebral A
accumulation.
The extracellular deposits were composed of
many fine granules frequently associated with
microglial cells, as confirmed by double immunoflu-
orescence and WB with antibody directed to
activated microglia. Otherwise, reactive astrocytes
were only rarely associated with A deposits. These
observations are shared by previous research in non-
demented and AD patients. In AD, the accumulation
of A and other neuronal debris establishes chronic
inflammation. Sustained exposure to A and other
inflammatory mediators seems to be responsible for
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the functional impairment of microglial cells seen
around A deposits. There are two plausible explana-
tions for the association between A and microglial
cells: i) A in glial cells may originate from an inef-
ficient clearance of high levels of soluble A present
in the brain [24]; ii) A secreted from neurons may
be phagocytosed by glial cells in its early, non fibrous
form and then degraded [25]. The presence of amy-
loid deposits with a non-fibrillar conformation of the
protein associated with a lack of immunoreactivity
to X34 in neurons and glial cells supports the latter
hypothesis and suggests microglial involvement at a
very early stage of A deposition.
Notably, this is the first report to demonstrate the
presence of A peptides in cattle brain. Although a
small number of samples was tested by WB analy-
sis, the same A isoforms characterizing AD brains
were found in cattle brain, albeit consistently below
the A levels detected in human brains and whose
distribution, starting from frontal to caudal brain
regions, was similar to that observed in AD patients
[26]. Biochemical cellular fractionation analyzed by
SELDI TOF-MS revealed the presence of 12 dif-
ferent A peptides, the majority of which are also
abundantly expressed in cognitively healthy humans,
schizophrenics, and AD patients [27]. Although in
our samples the Tris fraction was poorly indicative
in general, the Triton fraction (intracellular solu-
ble) showed a greater expression of A 1–37 and
1–40, peptides that have also been found in the cere-
brospinal fluid of AD patients and controls [28].
FA-insoluble fraction showed a greater expression of
A 1–34 and 1–42 that increase with the age of the
animals, as described in dogs [29], AD and healthy
aged humans, APP-transgenic mice and primates
[30, 31], although non statistically significant. Owing
to the small sample size, a consistent correlation
could not be found between the presence of A pep-
tides and IHC deposition patterns. In particular, the
presence of A 10–40 and A42 was associated with
the IHC extracellular deposition pattern in the frontal
cortex. The association with the A42 isoform was
not surprising because it is well described in human
AD brains and other animal species, including dogs
[32], cats [33], and monkeys [34]. More peculiar was
the association with A 10–40, a peptide that con-
tains all the structure-forming peptide segments of the
full-length sequence, except for the N-terminal seg-
ment previously determined to be unstructured in A
1–40 fibrillar assemblies. A study by Paravastu et al.
showed that omission of residues 1–9 did not prevent
the peptide from forming amyloid fibrils or elimi-
nate fibril polymorphism [35], whereby, expressing
such peptides, it is important not to underestimate the
potential of bovine species to form amyloid plaques.
The genetic variability of three genes involved
in AD pathogenesis was explored to unravel pos-
sible associations with A deposition in cattle. We
sequenced the complete ORF of the bovine APOE
gene and identified nine SNPs, none involving posi-
tions 112 and 158 of the homologous human gene.
Only one mutation determines a change in the amino
acid composition of the resulting APOE protein, but
it is located in the N-terminus of the protein and
was detected at very low frequency. Interestingly,
statistical analysis revealed a significant association
between APOE allele 725-T and the presence at WB
of A peptides 1–38, 1–40, and 1–42 in the cortex,
whereas the absence in the WB profile of peptide A
1–38 in the cortex was associated with alleles 133-G
and 824-G. These polymorphisms were not identified
in the coding region, but they were located in introns 2
and 3. Given the limited number of animals involved
in this study, caution is warranted. Should this associ-
ation be confirmed by future studies involving a larger
number of animals, these alleles might be hypothe-
sized to contribute to the control of gene expression
and, consequently, of APOE dosage. Many genes
have conserved regulatory regions located within
intron sequences; the enhancer effects of these con-
trol regions are so essential that some genes will not
be expressed in their absence [36].
We analyzed the complete PSEN1 ORF of 19
cattle and found no SNPs. Nevertheless, statistical
analysis showed a significant association between
allele 290 302ins GTACGTAGCCAG and the
absence of peptide 1–33 in the formic-acid fraction
of the cortex. This indel polymorphism determines
the presence/absence of four additional amino acid
residues in the PSEN1 protein and might influence
the ability of -secretase to cleave APP. The limited
genetic variability of bovine PSEN1, as compared
with the homologous human gene, seems to suggest
that PSEN1 does not play a primary role in modulat-
ing A deposition in cattle brain. The bovine PSEN2
gene is located on chromosome 16 and consists of 14
total exons (exons 5–14 coding). We identified five
mutations by analysing 18 PSEN2 ORFs. Interest-
ingly, the deletion of one glutamic acid (Glu) residue
at codon 325 (973 975delAGA), in complete linkage
disequilibrium with a synonymous SNP at codon
283 (849 G/A), was significantly associated with
the absence of A peptide 1–34 in the formic-acid
fraction of the cortex. This allele also showed a trend
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for correlation with the presence of intracellular A
deposition on IHC analysis. Here, we report this novel
mutation, which does not correspond to any human
PSEN2 mutation recorded in the Alzheimer Disease
& Frontotemporal Dementia Mutation Database
(http://www.molgen.ua.ac.be/ADMutations/). The
glu deletion occurs in the hydrophilic loop (HL)
domain of PSEN2, located between transmembrane
domains 6 and 7. Hydrophobic domains of both
presenilins are highly evolutionarily conserved,
with limited variability in amino acid sequences for
structural and functional reasons. In particular, the
HL domain between transmembrane domains 6 and
7 is thought to contain sites for phosphorylation,
caspase cleavage, and sequences that bind several
presenilin-interacting proteins.
In conclusion, this is the first study that fully
characterizes A deposition in cattle brain. Since
the bovine species possesses the same amino acid
sequence of APP as humans and displays the same
A fragments found in human brain, it provides an
interesting model to study the lack of aggregability
of A peptides and the role of glial cells in the early
stages of A deposition. Further studies are needed
to establish the involvement of other genes or epige-
netic factors able to modulate A fibril formation in
cattle brain.
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